Teroxalene is a dioxopiperazine derivative with multidrug resistance reversal activity

Isoflupredone is a veterinary drug used in cows, pigs and horses for the treatment of wide range of conditions: ketosis, musculoskeletal disorders, hypersensitivity, infections, inflammatory diseases, etc. The drug belongs to the class of corticosteroids and exerts its therapeutic effect by binding to glucocorticoid and mineralocorticoid receptors of animals.

Prozapine (hexadiphane), 1,l-diphenyl-3-hexamethyleneimino propane is a papaverine-like compound with weak anticholinergic activity. It has been used as an antispasmodic in the form of the hydrochloride, in combination with sorbitol, in biliary and gastro-intestinal disorders.

Fasoracetam is a cognition enhancer that interacts with GABA(B) receptors, stimulates neuronal ACh receptors and modulates mGlu receptors. The drug is being tested in phase III/II of clinical trials for the treatment of Attention Deficit Disorder With Hyperactivity in people with genetic disorders impacting mGlu receptors and never been approved by FDA. Fasoracetam is also being marketed in the form of capsules for research purposes aimed at investigation of cognition and memory disorders.

NELTENEXINE, an amide derivative of ambroxol and thiophenecarboxylic acid, is a mucolytic agent. It is an elastase inhibitor used in the treatment of human lung diseases.

Nepinalone is a new alchilaminate derivative of β-tetralone, which possess a non-opioid antitussive activity. Nepinalone racemus exerted a significant antitussive activity and both L- and D-isomers confirmed to possess a significant dose-correlated antitussive effect with better trend of activity for D-isomer, but not statistically significant. It was predicted to act via sigma receptors. Occasionally, episodes of gastric intolerance have been reported and rapidly receded when treatment was stopped. The use of doses higher than those recommended could cause drowsiness.

Zoniclezole was proven to have anticonvulsant profile. It is representative of a novel class of water-soluble agents being developed for the treatment of epilepsy. Zoniclezole has been shown to be a potential antagonist of electroshock-induced seizures in animals, and to some degree, pentylenetetrazol-induced seizures. In preclinical studies the compound had prolonged efficacy at relatively low doses. Zoniclezole is glutamate receptor antagonist.